Mukherjee and his co-workers have identified several genes and chemicals that can alter the microenvironment, or niche, and thereby alter the behavior of normal stem cells, as well as cancer cells.[26][27][28][29][30][31] Two such chemicals – proteasome inhibitors[26] and activin inhibitors[32] – are under clinical trials.[33][34] Mukerjee's lab has also identified novel genetic mutations in myelodysplasia and acute myelogenous leukaemia and has played a leading role in finding therapies for these diseases.[35][36]